ES2721666T3 - Composición farmacéutica sólida que contiene 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo - Google Patents
Composición farmacéutica sólida que contiene 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo Download PDFInfo
- Publication number
- ES2721666T3 ES2721666T3 ES13752248T ES13752248T ES2721666T3 ES 2721666 T3 ES2721666 T3 ES 2721666T3 ES 13752248 T ES13752248 T ES 13752248T ES 13752248 T ES13752248 T ES 13752248T ES 2721666 T3 ES2721666 T3 ES 2721666T3
- Authority
- ES
- Spain
- Prior art keywords
- azetidin
- benzothiophene
- ethoxy
- propyl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HQNACSFBDBYLJP-UHFFFAOYSA-N 1-[3-[2-(1-benzothiophen-5-yl)ethoxy]propyl]azetidin-3-ol Chemical compound C1C(O)CN1CCCOCCC1=CC=C(SC=C2)C2=C1 HQNACSFBDBYLJP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- XPRVSYXHPUYSGF-UHFFFAOYSA-N azetidin-3-one Chemical compound O=C1CNC1 XPRVSYXHPUYSGF-UHFFFAOYSA-N 0.000 abstract 1
- 239000000905 isomalt Substances 0.000 abstract 1
- 235000010439 isomalt Nutrition 0.000 abstract 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012035710 | 2012-02-22 | ||
| PCT/JP2013/054268 WO2013125617A1 (ja) | 2012-02-22 | 2013-02-21 | １－（３－（２－（１－ベンゾチオフェン－５－イル）エトキシ）プロピル）アゼチジン－３－オールまたはその塩を含有する固形医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2721666T3 true ES2721666T3 (es) | 2019-08-02 |
Family
ID=49005796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13752248T Active ES2721666T3 (es) | 2012-02-22 | 2013-02-21 | Composición farmacéutica sólida que contiene 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9872914B2 (enExample) |
| EP (1) | EP2818165B1 (enExample) |
| JP (1) | JP6054940B2 (enExample) |
| KR (1) | KR102070581B1 (enExample) |
| CN (1) | CN104159583B (enExample) |
| BR (1) | BR112014020434B1 (enExample) |
| CA (1) | CA2865380C (enExample) |
| DK (1) | DK2818165T3 (enExample) |
| ES (1) | ES2721666T3 (enExample) |
| IN (1) | IN2014DN06995A (enExample) |
| PL (1) | PL2818165T3 (enExample) |
| RU (1) | RU2625767C2 (enExample) |
| TR (1) | TR201907882T4 (enExample) |
| WO (1) | WO2013125617A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102092002B1 (ko) * | 2012-04-27 | 2020-03-23 | 메르크 파텐트 게엠베하 | 코팅이 있는 정제 및 이의 제조 |
| WO2015115512A1 (ja) | 2014-01-29 | 2015-08-06 | 独立行政法人産業技術総合研究所 | シクロデキストリンの利用による抗がん活性が増強されたアシュワガンダ葉の水抽出物の調製方法、及びアシュワガンダ葉を含む医薬組成物 |
| DK3395342T3 (da) * | 2015-12-25 | 2020-10-12 | Fujifilm Toyama Chemical Co Ltd | Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf |
| WO2018124283A1 (ja) | 2016-12-28 | 2018-07-05 | 富山化学工業株式会社 | 医薬組成物 |
| EP3563847B1 (en) * | 2016-12-28 | 2023-09-20 | FUJIFILM Toyama Chemical Co., Ltd. | Pharmaceutical composition |
| CN110167552B (zh) * | 2016-12-28 | 2023-05-02 | 富士胶片富山化学株式会社 | 医药组合物及其制造方法 |
| CN110139641B (zh) * | 2016-12-28 | 2022-09-09 | 富士胶片富山化学株式会社 | 外用组合物 |
| CA3067456C (en) * | 2017-06-02 | 2023-03-14 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating tauopathy |
| US11666551B2 (en) * | 2017-06-02 | 2023-06-06 | Fujifilm Toyama Chemical Co., Ltd. | Agent for reducing amount of amyloid β protein |
| WO2018221728A1 (ja) | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | アルツハイマー型認知症予防または治療剤 |
| US11951092B2 (en) * | 2017-06-02 | 2024-04-09 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating brain atrophy |
| AU2018277981B2 (en) * | 2017-06-02 | 2021-04-08 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating spinocerebellar ataxia |
| EP3705121B1 (en) | 2017-10-30 | 2023-08-30 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002088374A1 (fr) * | 2001-04-27 | 2002-11-07 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Processus de production d'isomaltose et utilisation de celui-ci |
| JP4905752B2 (ja) | 2001-07-24 | 2012-03-28 | エスティー・ラボ株式会社 | 揮発性有機塩素化合物センサ |
| PL217872B1 (pl) | 2001-10-19 | 2014-08-29 | Toyama Chemical Co Ltd | Pochodna eteru alkilowego lub jej sól, stanowiąca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól |
| US7118765B2 (en) * | 2001-12-17 | 2006-10-10 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
| JP4090309B2 (ja) | 2002-08-30 | 2008-05-28 | 帝人株式会社 | 全芳香族ポリエステルカーボネート系樹脂組成物 |
| NZ543100A (en) * | 2003-04-17 | 2008-07-31 | Toyama Chemical Co Ltd | Preventive/remedy for retinal nerve dieases containing alkyl ether derivatives or salts thereof |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| WO2006058250A2 (en) * | 2004-11-24 | 2006-06-01 | Spi Pharma, Inc. | Orally disintegrating compositions |
| RU2397169C2 (ru) * | 2005-03-28 | 2010-08-20 | Тояма Кемикал Ко., Лтд. | Способ получения 1-(3-(2-(1-бензотиофен-5-ил)этокси) пропил)азетидин-3-ола или его солей |
| ZA200708262B (en) | 2005-03-28 | 2009-01-28 | Toyama Chemical Co Ltd | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propyl)azetidin-3-ol or salts thereof |
| JP2007137802A (ja) * | 2005-11-16 | 2007-06-07 | Takeda Chem Ind Ltd | 錠剤の製造法 |
| US20070196494A1 (en) * | 2006-02-17 | 2007-08-23 | Arnaud Grenier | Low-friability, patient-friendly orally disintegrating formulations |
| BRPI0709909A2 (pt) * | 2006-03-31 | 2011-07-26 | Rubicon Res Private Ltd | tabletes de desintegraÇço oral |
| US8119625B2 (en) * | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| EP2048145B9 (en) * | 2006-08-04 | 2011-05-04 | Toyama Chemical Co., Ltd. | Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof |
| EP2211836A2 (en) * | 2007-10-10 | 2010-08-04 | Rubicon Research Private Limited | Taste-masked orally disintegrating tablets of memantine hydrochloride |
| EP2287160B1 (en) * | 2008-05-28 | 2014-05-07 | Toyama Chemical Co., Ltd. | Benzothiophene oxide derivative and salt thereof |
-
2013
- 2013-02-21 US US14/379,960 patent/US9872914B2/en active Active
- 2013-02-21 DK DK13752248.8T patent/DK2818165T3/da active
- 2013-02-21 TR TR2019/07882T patent/TR201907882T4/tr unknown
- 2013-02-21 JP JP2014500753A patent/JP6054940B2/ja active Active
- 2013-02-21 CN CN201380010472.9A patent/CN104159583B/zh active Active
- 2013-02-21 WO PCT/JP2013/054268 patent/WO2013125617A1/ja not_active Ceased
- 2013-02-21 EP EP13752248.8A patent/EP2818165B1/en active Active
- 2013-02-21 RU RU2014138035A patent/RU2625767C2/ru active
- 2013-02-21 BR BR112014020434-9A patent/BR112014020434B1/pt active IP Right Grant
- 2013-02-21 IN IN6995DEN2014 patent/IN2014DN06995A/en unknown
- 2013-02-21 KR KR1020147023511A patent/KR102070581B1/ko active Active
- 2013-02-21 CA CA2865380A patent/CA2865380C/en active Active
- 2013-02-21 ES ES13752248T patent/ES2721666T3/es active Active
- 2013-02-21 PL PL13752248T patent/PL2818165T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2818165B1 (en) | 2019-04-10 |
| PL2818165T3 (pl) | 2019-09-30 |
| KR102070581B1 (ko) | 2020-01-29 |
| CA2865380A1 (en) | 2013-08-29 |
| CA2865380C (en) | 2019-10-29 |
| CN104159583A (zh) | 2014-11-19 |
| EP2818165A4 (en) | 2015-07-08 |
| JPWO2013125617A1 (ja) | 2015-07-30 |
| EP2818165A1 (en) | 2014-12-31 |
| TR201907882T4 (tr) | 2019-06-21 |
| US9872914B2 (en) | 2018-01-23 |
| CN104159583B (zh) | 2018-04-13 |
| KR20150001720A (ko) | 2015-01-06 |
| BR112014020434B1 (pt) | 2021-10-13 |
| RU2014138035A (ru) | 2016-04-10 |
| WO2013125617A1 (ja) | 2013-08-29 |
| US20150045345A1 (en) | 2015-02-12 |
| DK2818165T3 (da) | 2019-06-03 |
| RU2625767C2 (ru) | 2017-07-18 |
| JP6054940B2 (ja) | 2016-12-27 |
| BR112014020434A2 (enExample) | 2017-06-20 |
| IN2014DN06995A (enExample) | 2015-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2721666T3 (es) | Composición farmacéutica sólida que contiene 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo | |
| MA41212A (fr) | Composition de soin oral contenant des cannabinoïdes | |
| CO2017002714A2 (es) | Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo | |
| CL2016001458A1 (es) | Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo. | |
| PT3433232T (pt) | Novo sal de adição de ácido de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina | |
| PE20150617A1 (es) | Formas solidas de 3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona o un estereoisomero del mismo, de sus sales, y composiciones que comprenden las mismas | |
| UY36315A (es) | COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. | |
| EP3256138A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH MELOXICAM | |
| CO6950480A2 (es) | Tableta que contiene 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona o una de sus sales | |
| ITMI20131102A1 (it) | Gestione harq-ack per subframe di dowlink non intenzionali | |
| HUE052421T2 (hu) | (2S)-N-[(1S)-1-ciano-2-feniletil]-l,4-oxazepan-2-karboxamidok dipeptidil-peptidáz I inhibitorokként | |
| CO7121351A2 (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
| EP2900774A4 (en) | RADIATION-HARDENED INK COMPOSITIONS | |
| DK3395342T3 (da) | Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf | |
| EP2868596A4 (en) | CONTAINER | |
| EP2894218A4 (en) | MEDIUM FOR BREEDING CORNEAL DENTHELIAL CELLS WITH A CONDITIONED MEDIUM OF MESENCHYMAL STEM CELLS | |
| CR20130147A (es) | Combinaciones que contienen n-(2-arilamino)arilsulfonamida sustituida | |
| EP2753329A4 (en) | 1,5-Naphthyridine inhibitor and Melk inhibitor with it | |
| CL2016001172A1 (es) | Nuevos inhibidores de dgat2. | |
| AR088297A1 (es) | R(+)-n-formil-propargil-aminoindano | |
| DK3103453T3 (da) | Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel | |
| UY34856A (es) | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida | |
| CR20120192A (es) | Nueva asociación entre la 4{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen | |
| CO6920289A2 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib. | |
| MX2018004979A (es) | Compuesto piranodipiridinico. |